ENA Respiratory is a clinical-stage pharmaceutical company developing antiviral host defense enhancers for the prevention of severe in at-risk complications from respiratory viral infections in vulnerable populations.
The company’s lead product is INNA-051, a first-in-class TLR2/6 agonist developed as a convenient, self-administered nasal product with a weekly dosing regimen.
INNA-051 works by priming and boosting the body’s natural first line of defence at the primary entry site of viral respiratory infections in the upper respiratory tract. This leads to accelerated viral clearance and reduced virus dissemination to the lower airways (lungs).
INNA-051 clinical development is led by an experienced team of clinicians and drug developers who have a deep understanding of respiratory diseases and a track record of bringing multiple new respiratory treatments to the US and other markets.
We are focused on improving the lives of vulnerable populations at risk of complications from respiratory viral infections and minimising the burden on the health care system.
INNA-051 has been shown in preclinical and clinical studies to be effective against multiple respiratory viruses and has demonstrated a favourable safety profile that supports seasonal prophylactic use and a fast onset of action with a durable response to enable weekly dosing.
ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
ENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer